Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Obesity Medicine
•
General Primary Care
In patients with BMI <30 but with obesity-related comorbidities (e.g., OSA, prediabetes, NAFLD), how comfortable are you initiating GLP-1s?
Related Questions
Would you consider pharmacotherapy (i.e., GLP1-agonist) or behavioral/nutrition interventions alone in a patient with a remote history of a restrictive eating disorder now presenting with obesity and metabolic complications?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
In patients with iron deficiency due to history of gastric bypass or IBD, would you consider oral iron therapy if the iron deficiency anemia is mild?
How many days prior to elective major surgery do you recommend holding oral GLP 1 R agonist therapy?
How do you counsel someone about metformin use for type 2 diabetes mellitus who is also on a GLP-1 agonist and achieved goal HbA1c, but prefers not to be on metformin anymore?
In what situations would you recommend metformin in addition to aggressive lifestyle interventions for patients with prediabetes and obesity?
Would you recommend a GLP-1 agonist as an option to reduce the risk of dementia in patients with a strong family history?
Outside of their use in performance anxiety, have you tried or found benefit with a daily beta blocker for generalized anxiety?
What is your approach when a female patient does not want a male MA/scribe present in the exam room but other staff are unavailable?
In patients on long-term proton pump inhibitors for GERD with stable symptoms, do you routinely attempt discontinuation or continue indefinitely given relapse risk?
